It’s a year of growth for clinical-stage biotech company Verismo Therapeutics.
The University City-based company is developing therapeutics designed to improve persistence and efficacy against aggressive solid tumors — specifically, multi-chain KIR-CAR platform technology for CAR T-cells. It welcomed Chief Scientific Officer Laura Johnson last October, and Senior Director of Translational Science in Jun Xu in the spring, to bring their experiences in process development and drug product characterization to the venture. And in September, the company received clearance of its Investigational New Drug application from the US Food and Drug Administration to initiate a first-in-human Phase 1 clinical trial of its SynKIR-110 therapy. The trial assesses the product’s safety, tolerability and preliminary efficacy in patients with mesothelin-expressing ovarian cancer, cholangiocarcinoma and mesothelioma.
READ FULL ARTICLE HERE
